RxDoctor Payments DataLook up a doctor →

Lily Chao

Pediatric Endocrinology · Los Angeles, CANPI 1508031352

Payments from drug & device makers

$2,209,635in general payments, 2019–2025

Across 4,228 payments — averaging $522.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1M
  • Novo Nordisk AS$562K
  • Merck$542K
  • Takeda Pharmaceuticals U.S.A., Inc.$90K
  • Dexcom, Inc.$9K
  • Sanofi-aventis U.S. LLC$3K
  • plus $3K from 6 others
$1,956in research payments, 2019–2025

Across 4 payments — averaging $488.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,209,635 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.

See all pediatric endocrinology providers in California

Other pediatric endocrinology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →